Astellas Pharma US has teamed up with Desert Oasis Healthcare (DOHC), a part of Heritage Provider Network, to pilot the DIGITIVA solution for heart care management.
Established in 1981, DOHC offers primary and immediate care, home health, palliative care, clinical research studies and other services to more than 60,000 members.
DIGITIVA is a non-invasive digital health solution designed to improve care management for heart failure patients.
Under the partnership, eligible patients at DOHC will start receiving care using the DIGITIVA solution as a new method for managing their heart health, in the next few weeks.
The collaboration will collect DIGITIVA data based on key clinical measures and metrics relevant to patients, healthcare providers and the healthcare system.
In addition, the patients will complete the Kansas City Cardiomyopathy Questionnaire (KCCQ), which evaluates their perception of heart failure symptoms and quality of life.
Desert Oasis Healthcare clinical operations and Network ACO heritage provider executive vice president Brian Hodgkins said: “DIGITIVA exemplifies Desert Oasis Healthcare’s commitment to exploring innovative health technologies with the potential to better the lives of both patients and providers.
“Placing patients at the centre of their care, DIGITIVA provides enhanced heart health data tracking, automated feedback and educational resources from home, while equipping clinicians with patient-specific data potentially signalling when earlier intervention could be beneficial.
“Desert Oasis Healthcare is proud to be the first health system in the country to provide patients and cardiology providers with access to DIGITIVA and look forward to better understanding its potential impact.”
The DIGITIVA solution comprises the CORE 500 Digital Stethoscope developed by Eko Health and a smartphone app built on the Welldoc platform.
It also provides AI-powered personalised digital coaching, along with educational resources from the American Heart Association,
The clinicians using the DIGITIVA solution will receive personalised patient reports evaluated by a clinical review team.
The reports would highlight relevant cardio-acoustic biomarkers, and physiological parameters to enable earlier intervention, said Astellas.
Astellas Rx+ business accelerator and DIGITIVA program lead Patrick Keenan said: “Implementing DIGITIVA in a real-world setting represents a significant achievement as the first SaMD and medical device offering from Astellas in the US.
“Working closely with Desert Oasis Healthcare, we look forward to demonstrating the potential of DIGITIVA to improve patient outcomes by supporting patients’ ability to take a more active role in managing their health, as well as providing clinicians with personalised information that can inform important clinical decisions.”
